News & Events
 
The Drugs Technical Advisory Board has examined the issue of suspension of manufacture and sale of Pioglitazone on 19th July 2013 & has recommended that the Suspension of the drug should be revoked and allowed to be marketed subject to certain conditions the manufacturers shall mention on their package insert and promotional literature of the drug. Based on DTAB report Ministry of health & family welfare & Central Government revokes the notification G.S.R.379(E) dated 18th June 2013.
-------------------------------
A new study presented at EULAR 2013,the Annual Congress of the European League Against Rheumatism shows that one in eight patients at risk of developing a serious adverse drug event (ADE) is taking over the counter (OTC) non-steroidal anti-inflammatory drugs (NSAIDs), often to treat a musculoskeletal complaint Possible serious ADEs include gastrointestinal bleeding, peptic ulceration, high blood pressureand worsening heart failure.
-------------------------------
Researchers reported at the American Heart Association's 50th Annual Conference on Cardiovascular Disease Epidemiology and Prevention, that the increase in sugar consumption has led to more diabetes and heart disease over the past decade.
-------------------------------
Researchers reported at the American Heart Association's 50th Annual Conference on Cardiovascular Disease Epidemiology and Prevention, that the increase in sugar consumption has led to more diabetes and heart disease over the past decade.

Testimonials
Slideshow Image 1
Slideshow Image 2
Slideshow Image 1
Slideshow Image 2
Slideshow Image 1
 
     
 
 Telmisartan & Amlodipine Tablets

 
  COMPOSITION:  
  ONTEL™ AM: Each uncoated tablet contains: Telmisartan IP 40mg and Amlodipine Besylate IP equivalent to Amlodipine 5 mg.  
     
  THERAPEUTIC INDICATIONS:  
  Indicated for the treatment of essential hypertension  
     
  DOSAGE AND ADMINISTRATION:  
 
The usual starting dose of Telmisartan and Amlodipine tablets is 40/5 mg OD.Dosage must be individualized. The maximumrecommended dose is 80/10 mg OD.Tablets may be taken with or without food.
 
     
  CONTRAINDICATIONS :  
 
In patients with known hypersensitivity (e.g., anaphylaxis or angioedema) to telmisartan or any other component of this product.
 
     
  WARNINGS & PRECAUTIONS:  
 
Telmisartan can cause fetal/neonatal morbidity and mortality when administered to pregnant women. Symptomatic hypotension may occur after initiation of therapy with telmisartan & amlodipine tablets. Hyperkalemia may occur in patients on ARBs (angiotensin-renin blockers), particularly in patients with advanced renal impairment, heart failure, on renal replacement therapy, or on potassium supplements, potassium-sparing diuretics, potassium-containing salt substitutes or other drugs that increase potassium levels. Not recommended in hepatically impaired patients. Changes in renal function may be anticipated in susceptible individuals using telmisartan. Dual blockade of the renin-angiotensin-aldosterone system should include close monitoring of renal function. Patients with severe obstructive coronary artery disease have developed documented increased frequency, duration or severity of angina or acute myocardial infarction with calcium channel blockers. Closely monitor patients with heart failure.
 
     
  PREGNANCY & LACTATION:  
  When pregnancy is detected, discontinue Ontel AM as soon as possible. Potential for adverse effects on nursing infant, discontinue nursing or the drug taking into account the importance of the drug to the mother. Safety and efficacy in paediatric patients has not been established.  
     
  ADVERSE REACTIONS :  
 
Most frequently spontaneously reported events caused by telmisartan include: headache, dizziness, asthenia, coughing, nausea, fatigue, weakness, edema, face edema, lower limb edema, angioneurotic edema, urticaria, hypersensitivity, sweating increased, erythema, chest pain, atrial fibrillation, congestive heart failure, myocardial infarction, blood pressure increased, hypertension aggravated, hypotension (including postural hypotension), hyperkalemia, syncope, dyspepsia, diarrhea, pain, urinary tract infection, erectile dysfunction, back pain, abdominal pain, muscle cramps (including leg cramps), myalgia, bradycardia, eosinophilia, thrombocytopenia, uric acid increased, abnormal hepatic function/liver disorder, renal impairment including acute renal failure, anemia, and increased CPK, anaphylactic reaction, and tendon pain (including tendonitis, tenosynovitis), drug eruption, hypoglycemia (in diabetic patients) and angioedema. Most common side effects of amlodipine were headache and oedema in clinical trials.
 
     
  Back to Products  

 

 

         
 
 
Home | About Us | Products | Enquiry | Contact Us | Order | Carrer
     
  All Rights Reserved By : Cadell Health care Pvt Ltd. Designed & Maintained By : Daffodil Design & Prints